NEW YORK - (NewMediaWire) - November 1, 2024 - Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS’ patented drug screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Intelligent Bio Solutions has joined B2i Digital's Portfolio of Featured Companies
- B2i Digital will highlight Intelligent Bio Solutions's unique value proposition through its social media channels with nearly 1 million followers
- B2i Digital's investor-focused marketing strategies will raise awareness of INBS' patented drug screening technology
Click image above to view full announcement.
About B2i Digital, Inc.
B2i Digital, Inc. leverages the latest digital marketing technologies to tell a company’s story to retail investors, institutional investors, and research analysts. B2i Digital creates robust profiles for companies on its platform, b2idigital.com, and launches targeted digital marketing campaigns to bring the most relevant investors to each company based on its sector, stage in its capital markets evolution, and overall company story. The company was founded in 2021 by David Shapiro, previously an investment banker and Chief Marketing Officer at Maxim Group LLC and one of the founders of Maxim's investor awareness platform, M-Vest.com.
B2i Digital Contact Information:
David Shapiro
Chief Executive Officer
B2i Digital, Inc.
212.579.4844 Office
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
Intelligent Bio Solutions Investor & Media Contact:Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com